ConductScience.org, home

Paper40934005

Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.

Tang XF and 9 others. Front Immunol, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin. Papers, record 40934005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40934005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-09-15
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tang XFXiang-Feng
2Luo YHYan-Hui
3Si YJYing-Jian
4Qin MQMao-Quan
5Lu WWei
6Chen WWei
7Xing GSGuo-Sheng
8Cao WWei
9Zhou HFHai-Fei
10Liu XJXiang-Jun

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, KIRMajor topic
Killer Cells, NaturalMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
HLA AntigensMajor topic
Transplantation, HaploidenticalMajor topic
Antilymphocyte SerumMajor topic
Humans
Child
Male
Female
Child, Preschool
Adolescent
Recurrence
Retrospective Studies
Infant
Graft vs Host Disease

Source PubMed

Download CSV of topics

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119961944Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.Biol Blood Marrow Transplant2010https://conductscience.org/library/papers/19961944PubMed
238369017Donor KIR2DL1 Allelic Polymorphism Influences Posthematopoietic Progenitor Cell Transplantation Outcomes in the T Cell Depleted and Reduced Intensity Conditioning Setting.Transplant Cell Ther2024https://conductscience.org/library/papers/38369017PubMed
338629074Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.Front Immunol2024https://conductscience.org/library/papers/38629074PubMed
429358179Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.Blood2018https://conductscience.org/library/papers/29358179PubMed
532267930Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia.Blood Adv2020https://conductscience.org/library/papers/32267930PubMed
635242134KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection.Front Immunol2022https://conductscience.org/library/papers/35242134PubMed
720581313Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.Blood2010https://conductscience.org/library/papers/20581313PubMed
824748496Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.J Immunol2014https://conductscience.org/library/papers/24748496PubMed
927998801The impact of KIR2DS4 gene on clinical outcome after hematopoietic stem cell transplantation.Hum Immunol2017https://conductscience.org/library/papers/27998801PubMed
1022139069
Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.
Bone Marrow Transplant2012https://conductscience.org/library/papers/22139069PubMed
1124043749Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.J Clin Oncol2013https://conductscience.org/library/papers/24043749PubMed
1233542712Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.Front Immunol2020https://conductscience.org/library/papers/33542712PubMed
1330787107Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.J Immunol2019https://conductscience.org/library/papers/30787107PubMed
1418945967
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Blood2009https://conductscience.org/library/papers/18945967PubMed
1533767404Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.Bone Marrow Transplant2021https://conductscience.org/library/papers/33767404PubMed
1638052043Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.Blood Adv2024https://conductscience.org/library/papers/38052043PubMed
1717268518Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion.Leukemia2007https://conductscience.org/library/papers/17268518PubMed
1836311784Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy.Front Immunol2022https://conductscience.org/library/papers/36311784PubMed
1928520526KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.J Clin Oncol2017https://conductscience.org/library/papers/28520526PubMed
2022931314HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.N Engl J Med2012https://conductscience.org/library/papers/22931314PubMed

See all 33 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42712389Contrasting relapse rate associated with the absence of HLA-A3/A11 in T cell-replete haploidentical transplantation.Front Immunol2026https://conductscience.org/library/papers/42712389

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
HLA-A3105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
KIR2DS13806PubTator's text mininghttps://conductscience.org/library/genes/3806NCBI Gene
KIR3DL23812PubTator's text mininghttps://conductscience.org/library/genes/3812NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40934005

GET https://conductscience.org/api/papers/v1/40934005/references?page=2